| Identification | Back Directory | [Name]
Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- | [CAS]
2170694-04-7 | [Synonyms]
IRAK4-IN-21
Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- | [Molecular Formula]
C28H28FN7O2 | [MOL File]
2170694-04-7.mol | [Molecular Weight]
513.57 |
| Chemical Properties | Back Directory | [Boiling point ]
827.1±75.0 °C(Predicted) | [density ]
1.409±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
16.25±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis[1]. | [in vivo]
IRAK4-IN-21 (75 mg/kg; p.o.; single) shows moderate efficacy in acute animal model studies for the inhibition of IL-6 production[1]. | Animal Model: | BALB/c mice (acute mouse model; IL-1β-stimulated)[1]. | | Dosage: | 75 mg/kg | | Administration: | Oral administration; single (pre-treat). | | Result: | Showed 54% inhibition of IL-6, plasma concentrations was 2877 ng/mL at 0.5 h and 496 ng/mL at 2 h. |
| [References]
[1] Chen Y, et al. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors. ACS Med Chem Lett. 2022 Apr 4;13(4):714-719. DOI:10.1021/acsmedchemlett.2c00056 |
|
|